ResearcherPeking University Cancer HospitalActive in the last 2 years

Jun Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7154-3385; OpenAlex author ID A5101632519. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adeno… Co-author DOI 10.1038/s41392-025-02530-2 ↗
Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma. Last author DOI 10.2147/cmar.s263773 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Lin Shen · 2 shared papers, 2020–2025 · strength 0.37
- Paper A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitab… DOI 10.1038/s41392-025-02530-2 ↗
- Paper Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Ad… DOI 10.2147/cmar.s263773 ↗
Zhi-Hua Li · 1 shared paper, 2025 · strength 0.24
- Paper A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitab… DOI 10.1038/s41392-025-02530-2 ↗
Miaoyan Wei · 1 shared paper, 2025 · strength 0.24
- Paper A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitab… DOI 10.1038/s41392-025-02530-2 ↗
Ran Xue · 1 shared paper, 2025 · strength 0.24
- Paper A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitab… DOI 10.1038/s41392-025-02530-2 ↗
Xianjun Yu · 1 shared paper, 2025 · strength 0.24
- Paper A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitab… DOI 10.1038/s41392-025-02530-2 ↗
Yuhong Zhou · 1 shared paper, 2025 · strength 0.24
- Paper A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitab… DOI 10.1038/s41392-025-02530-2 ↗
Yuan Zong · 1 shared paper, 2020 · strength 0.13
- Paper Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Ad… DOI 10.2147/cmar.s263773 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.